ERV Reactivation Drives C4b-Mediated Synaptic Pruning in Autism Models

Unraveling Neuroinflammation in Autism Spectrum Disorders

The etiological complexity of autism spectrum disorders (ASDs) presents a significant clinical challenge, with a wide spectrum of presentations stemming from a mix of genetic, epigenetic, and environmental factors [1, 2]. A growing consensus in the field points toward neuroinflammation as a key pathological contributor, specifically involving the dysregulation of microglial cells [3, 4]. Microglia, the resident immune cells of the central nervous system, are essential for sculpting neural circuits through synaptic pruning. However, when this process becomes overactive, it can lead to excessive synapse loss and altered brain connectivity, a suspected substrate for ASD-related behaviors [5]. Identifying the specific molecular triggers that drive this aberrant microglial activity is therefore a critical step toward developing targeted therapies.

C4b and Synaptic Pruning: A Mechanistic Link in ASD

A recent study in mouse models has identified a convergent pathological pathway that may unify disparate risk factors for autism spectrum disorders. The researchers found that two distinct triggers, deficiency in the high-risk ASD gene SETDB1 and maternal immune activation (MIA) during gestation, both led to the same downstream effect: elevated expression of complement protein C4b. This upregulation was notably specific to neurons within the prefrontal cortex, a region integral to social behavior and executive function, providing a direct anatomical link to core ASD-related deficits. The study demonstrated that this neuronal C4b acts as a signal, triggering excessive synaptic pruning by microglia. While synaptic pruning is a necessary developmental process for refining neural circuits, the C4b-driven over-pruning led to a pathological reduction in synaptic density. This loss of connections was directly associated with the manifestation of autistic-like behaviors in the animal models, establishing a clear mechanistic cascade from initial insult to behavioral outcome.

Reversing Synaptic Dysfunction and Behavioral Phenotypes

To validate this proposed mechanism, the investigators performed a series of targeted interventions. First, to confirm the role of microglia as the cellular effectors of this damage, they tested the impact of their removal. The findings showed that microglia elimination improved synaptic density in the mice, directly implicating these immune cells in the observed synapse loss. This result suggests that modulating microglial activity could be a viable strategy for restoring synaptic health. To test the centrality of the complement protein itself, the researchers went a step further. In a separate experiment, they found that complete C4b knockout rescued all observed autistic-like phenotypes in the mice. The comprehensive reversal of behavioral deficits following the removal of this single protein strongly suggests that C4b is not merely a contributor but a critical node in this pathological pathway, making it a highly specific target for potential intervention.

Endogenous Retroviruses: A Driver of C4b Expression

Having established C4b as the key mediator of excessive pruning, the study next explored the upstream molecular events that drive its expression. The researchers discovered that the increase in C4b was driven by the formation of RNA-DNA hybrids within the neurons. These are stable molecular structures, formed when an RNA molecule binds to its corresponding DNA sequence, which can interfere with normal gene regulation. The investigation then traced the source of the RNA involved in these hybrids, uncovering a fascinating link to the host's own genome. They determined that the RNA-DNA hybrids are formed through the reactivation of endogenous retroviruses (ERVs). ERVs are remnants of ancient viral infections that have become permanently integrated into the human and mouse genomes. While these sequences are typically silenced, the study found that both SETDB1 deficiency and maternal immune activation caused them to be transcribed again, producing the RNA that ultimately drives pathological C4b expression.

Repurposing HIV Medications: A Potential Therapeutic Avenue

The discovery that endogenous retrovirus (ERV) reactivation drives this pathological cascade presented a logical therapeutic opportunity. The researchers hypothesized that drugs targeting the retroviral life cycle might interrupt the process. They tested this by administering existing FDA-approved HIV medications, which function by inhibiting retrotranscriptional activity. The results were compelling: the medications substantially reduced C4b levels in the mouse models, directly intervening in the pathway at its source. More importantly, this biochemical correction translated to behavioral improvements, as the HIV medications also alleviated autistic-like symptoms in the animals. This finding carries significant translational potential, as it suggests that a class of drugs with well-established safety profiles could be repurposed to address a core mechanism in certain forms of ASD. The study provides a comprehensive model from ERV reactivation to C4b-mediated synaptic pruning and highlights a potential treatment strategy worthy of further clinical investigation.

References

1. Hilal ML, Rosina E, Pedini G, Restivo L, Bagni C. Dysregulation of the mTOR-FMRP pathway and synaptic plasticity in an environmental model of ASD. Molecular Psychiatry. 2024. doi:10.1038/s41380-024-02805-0

2. Chen G, Geschwind DH. Challenges and opportunities for precision medicine in neurodevelopmental disorders. Advanced Drug Delivery Reviews. 2022. doi:10.1016/j.addr.2022.114564

3. Gardner Z, Holbrook O, Tian Y, Odamah K, Man H. The role of glia in the dysregulation of neuronal spinogenesis in Ube3a-dependent ASD. Experimental Neurology. 2024. doi:10.1016/j.expneurol.2024.114756

4. Tavares GA, O’Reilly L, Frederick NM, et al. Macrophage-mediated refinement of the dural lymphatic regulates social behavior. Neuron. 2026. doi:10.1016/j.neuron.2026.03.019

5. Russo CD, Cappoli N, Coletta I, et al. The human microglial HMC3 cell line: where do we stand? A systematic literature review. Journal of Neuroinflammation. 2018. doi:10.1186/s12974-018-1288-0